Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print March 1, 2006, doi:10.1212/01.wnl.0000204294.28189.03)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000204294.28189.03v1
66/6/919    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schifitto, G.
Right arrow Articles by Gelbard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schifitto, G.
Right arrow Articles by Gelbard, H.
Received August 10, 2005
Accepted December 29, 2005

Valproic acid adjunctive therapy for HIV-associated cognitive impairment. A first report

G. Schifitto MD*, D. R. Peterson PhD, J. Zhong PhD, H. Ni MS, K. Cruttenden MS, RN, M. Gaugh MA, H. E. Gendelman MD, M. Boska PhD, and H. Gelbard MD, PhD

From the Departments of Neurology (G.S., K.C., M.G., H.G.), Biostatistics (D.R.P.), and Radiology (J.Z., H.N.), University of Rochester Medical Center, Rochester, NY; and Departments of Pharmacology and Experimental Neuroscience (H.E.G.) and Radiology (M.B.), University of Nebraska Medical Center, Omaha.


* To whom correspondence should be addressed. E-mail: giovanni.schifitto{at}ctcc.rochester.edu.

Abstract-- In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. DiCenzo, D. R. Peterson, K. Cruttenden, P. Mariuz, N. L. Rezk, J. Hochreiter, H. Gelbard, and G. Schifitto
Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3035 - 3039.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, et al.
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
Neurology, September 25, 2007; 69(13): 1314 - 1321.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.